Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

8 terminated/withdrawn out of 24 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

29%

7 trials in Phase 3/4

Results Transparency

31%

5 of 16 completed trials have results

Key Signals

5 with results7 terminated

Enrollment Performance

Analytics

Phase 2

15(62.5%)

Phase 3

6(25.0%)

Phase 1

1(4.2%)

N/A

1(4.2%)

Phase 4

1(4.2%)

24Total

Phase 2(15)

Phase 3(6)

Phase 1(1)

N/A(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials

NCT02377193Phase 4Completed

Simulect Versus ATG in Sensitized Renal Transplant Patient

Role: collaborator

NCT02757989Not ApplicableCompleted

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

Role: collaborator

NCT03866954Phase 2Withdrawn

Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy

Role: collaborator

NCT01582048Phase 2Terminated

Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Role: collaborator

NCT04971005Phase 2Terminated

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

Role: collaborator

NCT00140543Phase 3Completed

European Trial of Immunosuppression in SPK Tx

Role: collaborator

NCT01295710Phase 3Completed

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Role: lead

NCT00326885Phase 2Completed

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Role: lead

NCT01504256Phase 2Completed

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas

Role: collaborator

NCT01246440Phase 2Completed

Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission

Role: collaborator

NCT00351858Phase 2Terminated

Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

Role: lead

NCT01324934Phase 3Terminated

Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids

Role: lead

NCT00464893Phase 2Completed

Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection

Role: lead

NCT01320020Phase 1Terminated

A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

Role: lead

NCT00563836Phase 2Completed

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Role: lead

NCT01065246Phase 2Completed

Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites

Role: lead

NCT00822809Phase 3Completed

CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers

Role: lead

NCT00377429Phase 2Completed

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Role: lead

NCT00105183Phase 3Completed

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

Role: lead

NCT00655343Phase 3Completed

Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)

Role: lead